

Product Information

Aprotinin from bovine lung

Saline solution, 3-7 TIU/mg protein

A6279

Product Description

CAS Registry Number: 9087-70-1

Synonyms: Basic pancreatic trypsin inhibitor, Bovine pancreatic trypsin inhibitor (BPTI), Kallikrein-trypsin inactivator, Kunitz protease inhibitor


Molecular formula: $C_{284}H_{432}N_{84}O_{79}S_7$

Molecular weight: 6,512 Da

pI: 10.5

Extinction coefficient: $E^{1\%} = 8.4$ (280 nm, water)

Aprotinin is a protein consisting of 58 amino acids, arranged in a single polypeptide chain that is cross-linked by three disulfide bridges (depicted below). Aprotinin is a competitive serine protease inhibitor that forms stable complexes with and blocks the active sites of various enzymes, such as those listed in Table 1. The binding is reversible. Most aprotinin-protease complexes dissociate at pH >10 or pH < 3.



Several theses¹⁻⁶ and dissertations⁷⁻¹⁶ have cited use of product A6279 in their protocols.

Reagent

This product is an aseptically filled solution in 0.9% NaCl and 0.9% benzyl alcohol.

Inhibitory Activity:

- 3-7 TIU/mg protein
- 5-10 TIU/mL solution

Unit Definition: One Trypsin Inhibitor Unit (TIU) will decrease the activity of 2 trypsin units by 50%, where 1 trypsin unit will hydrolyze 1.0 μ mole of *N*- α -benzoyl-DL-arginine *p*-nitroanilide (BAPNA) per minute at pH 7.8 and 25 °C.

Another commonly used unit of activity is the KIU (Kallikrein Inhibitor Unit). Different conversion factors between aprotinin units have been reported:

- 1 TIU = 1,300 KIU
- 1 TIU = 1,025 KIU¹⁷

In general, aprotinin is freely soluble in water and in aqueous buffers of low ionic strengths.¹⁸ The aprotinin concentration in this product is in the range of ~ 2 mg/mL.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store this aprotinin solution at 2-8 °C. When properly stored and unopened at 2-8 °C, the product retains activity for at least 4 years.

MERCK

Dilute solutions of aprotinin are generally less stable than concentrated ones. Solution stability is pH-dependent, although a pH range of 1-12 can be tolerated.¹⁹ Repeated freeze-thaw cycles should be avoided.

The Cys¹⁴-Cys³⁸ disulfide bridge is readily split by reducing agents like 2-mercaptoethanol.¹⁹ Due to its compact tertiary structure, aprotinin is relatively stable against denaturation due to high temperature, organic solvents, or proteolytic degradation (See Table 2). Only thermolysin has been found capable of degrading aprotinin after heating to 60-80 °C.¹⁹

The high basicity of aprotinin causes it to adhere to commonly used dialysis tubing and even gel filtration matrices. However, the use of acetylated materials and concentrated salt solutions (such as ≥ 0.1 M NaCl in buffer) minimizes this problem.¹⁹

Sterilization may be achieved by filtration through a 0.2 µm filter.

References

- Knupp, Jacquelyn B., "The effect of TGF-β and EGF on MMP-2 activation and MT1-MMP phosphorylation in U87MG and T98G human glioma cells". University of Richmond, B.S. honors thesis, p. 12 (2006).
- Tran, Thuy Tien, "Modulation of Transforming Growth Factor β-induced endothelial-mesenchymal transition by NCK". Texas A&M University, Undergraduate Research Scholar thesis, p. 19 (2019).
- Subramanya, Gitanjali, "Role of Type II Transmembrane Serine Proteases in Coronavirus Production". Loyola University Chicago, M.S. thesis, p. 10 (2011).
- Cowens, Kylie Rose, "Effect of *in vivo* polybrominated diphenyl ether (PBDE) treatment on hepatic glycero-neogenesis and lipid metabolism". University of New Hampshire, M.S. thesis, p. 31 (2015).
- Goel, Raghuveera Kumar, "Phosphoproteomics Analyses to Identify the Candidate Substrates and Signaling Intermediates of the Non-Receptor Tyrosine Kinase, SRMS". University of Saskatchewan, M.Sc. thesis, p. 33 (2016).
- Vidales, Maria Del Mar Sanchez, "Release of Soluble Interleukin-7 α Receptor (CD127) from CD8⁺ T-Cells and Human Thymocytes". University of Ottawa, M.Sc. thesis, p. 28 (2016).
- Cooper, Peter S., "Expression of the xenobiotic transporter P-glycoprotein in the mummichog (*Fundulus heteroclitus*)". College of William and Mary, Ph.D. dissertation, pp. 38, 39, 64, 114 (1996).
- Bezugla, Yevgeniya, "Production of prostaglandin E₂ and thromboxane A₂ by rat liver macrophages and involvement of nitric oxide and cytokines in mediator pathways under inflammatory conditions". Technische Universität Dresden, Dr. rer. nat. dissertation, p. 26 (2008).
- Jo, Stephanie Youngyoon, "The role of Dot1l in normal hematopoiesis and MLL translocation leukemia". University of Michigan, Ph.D. dissertation, p. 74 (2011).
- Kim, Eun-Ji, "Localization and Dynamics of Myosin Vb in Mammalian Cells". University of Connecticut, Ph.D. dissertation, p. 21 (2013).
- Nguyen-Ngoc, Kim-Vy, "Novel roles of extracellular matrix and non-muscle myosin ii in regulating epithelial migration and proliferation". Johns Hopkins University, Ph.D. dissertation, p. 215 (2015).
- Schaffer, Bethany Eleanor, "Identification of Direct AMPK Phosphorylation Sites in Cells Reveals a Role for AMPK in Non-Metabolic Pathways". Stanford University, Ph.D. dissertation, p. 100 (2015).
- Swenson, Barbara Louise, "Identifying the Role of Janus Kinase 1 in Mammary Gland Development and Breast Cancer". University of Nebraska Medical Center, Ph.D. dissertation, p. 38 (2017).
- Matoug-Elwerfelli, Manal, "Decellularisation of the Dental Pulp for Use as a Scaffold in Regenerative Endodontics". University of Leeds, Ph.D. dissertation, p. 50 (2017).
- Geraldo-Aviles, Jose Gabino, "Dysregulation of microRNAs in Dementia". University of Bristol, Ph.D. dissertation, p. 44 (2019).
- Pérez, Laura González, "Role of the atypical CDK activator RINGO beyond meiosis". Universitat de Barcelona, Ph.D. dissertation, p. 72 (2019).
- Hewlett, G., *Biotechnology (NY)*, 565-566 (1990).
- Biochemica Information*, 1st ed. (J. Keesey, ed.). Boehringer Mannheim Biochemicals (Indianapolis, IN), p. 111 (1987).
- Fritz, H., and Wunderer, G., *Arzneimittelforschung*, **33(4)**, 479-494 (1983).
- Zollner, H. (ed.), *Handbook of Enzyme Inhibitors*, 2nd edition, Part B. VCH Verlagsgesellschaft (Weinheim, Germany), p. 572 (1993).
- Kunitz, M., and Northrop, J.H., *J. Gen. Physiol.*, **19(6)**, 991-1007 (1936).
- Sherman, M.P., and Kassell, B., *Biochemistry*, **7(10)**, 3634-3641 (1968).
- Zyznar, E.S., *Life Sci.*, **28(17)**, 1861-1866 (1981).

Table 1. Inhibition by Aprotinin

Enzyme (Source), Condition	Inhibition (K _i)
Acrosin	Weak inhibition ¹⁸
Chymotrypsin	K _i = 9 nM ²⁰
CMP- <i>N</i> -Acetyl-neuraminate lactosylceramide α-2,3-sialyltransferase	74% Inhibition at 300 nM ²⁰
Elastase (human leukocyte), pH 8.0	K _i = 3.5 μM ¹⁹
Kallikrein (pancreatic), pH 8.0	K _i = 1.0 nM ¹⁹
Kallikrein (plasma)	K _i = 30 nM; 100 nM ¹⁸
Kallikrein (tissue)	K _i = 1 nM ¹⁸
Kallikrein (urine)	K _i = 1.7 nM ¹⁸
Plasmin (porcine), pH 7.8	K _i = 4.0 nM ¹⁹
Plasminogen activator	K _i = 8 μM; 27 μM ¹⁸
Trypsin (bovine), pH 8.0	K _i = 0.06 pM ¹⁹
Trypsinogen (bovine), pH 8.0	K _i = 1.8 μM ¹⁹
Tryptase TL-2	16% Inhibition at 10 μM ¹⁸
Urokinase (human), pH 8.8	K _i = 8.0 μM ¹⁹

Table 2. Aprotinin solution stability

Solvent	Concentration	Temperature	% Loss/Time
Sterile water with 0.9% NaCl and 0.9% benzyl alcohol, pH 5.7-6.2	10 mg/mL	0-5 °C	< 4.3%/year
2.5% Trichloroacetic acid	N/A	80 °C	No loss ²¹
pH < 12.6	N/A	N/A	No loss observed after 24 hours ²²
pH < 12	N/A	N/A	Irreversibly denatured ²³
pH 7-8	0.065-1.95 μg/mL	4 °C	About 1 week ¹⁸
pH 7-8	0.065-1.95 μg/mL	-20 °C	> 6 months ¹⁸

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates
as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.
All other trademarks are the property of their respective owners. Detailed information on
trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

A6279pis Rev 06/22 RBG,MAC,GCY,MAM

